Novel therapeutic targets in rheumatoid arthritis

Highlights • Small molecule inhibitors targeting the JAK pathway are a promising new treatment strategy for RA. • The Th17 pathway, including IL-17, IL-21, IL-22, and GM-CSF, offers interesting new targets for RA. • Dual cytokine inhibition in RA might increase clinical response.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Trends in pharmacological sciences (Regular ed.) 2015-04, Vol.36 (4), p.189-195
Hauptverfasser:	Koenders, Marije I, van den Berg, Wim B
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Basic Science Animals Antirheumatic Agents - administration & dosage Antirheumatic Agents - metabolism Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - metabolism Cytokines - antagonists & inhibitors Cytokines - metabolism Drug Delivery Systems - trends Humans IL-17 JAK Janus Kinases - antagonists & inhibitors Janus Kinases - metabolism rheumatoid arthritis Th17 Th17 Cells - drug effects Th17 Cells - metabolism therapeutic targets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Small molecule inhibitors targeting the JAK pathway are a promising new treatment strategy for RA. • The Th17 pathway, including IL-17, IL-21, IL-22, and GM-CSF, offers interesting new targets for RA. • Dual cytokine inhibition in RA might increase clinical response.
ISSN:	0165-6147 1873-3735
DOI:	10.1016/j.tips.2015.02.001